Clinical Trial Detail

NCT ID	NCT04028063
Title	Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	University of Colorado, Denver
Indications	hemangiopericytoma pleomorphic liposarcoma myoepithelioma spindle cell sarcoma malignant peritoneal solitary fibrous tumor malignant pleural solitary fibrous tumor uterus leiomyosarcoma leiomyosarcoma synovial sarcoma dedifferentiated liposarcoma malignant peripheral nerve sheath tumor myxoid liposarcoma angiosarcoma myxofibrosarcoma sarcoma fibrosarcoma malignant epithelioid hemangioendothelioma
Therapies	Balstilimab + Doxorubicin + Zalifrelimab
Age Groups:	senior adult